As­traZeneca drops an OX40 can­cer drug can­di­date in Q4 pipeline cleanup

Q4 may have been a tri­umph in many re­spects, as As­traZeneca’s can­cer drugs con­tin­ue to carve out a big­ger fran­chise for the com­pa­ny — cru­cial for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.